Pulmonary hypertension in beta thalassemia: a prospective cohort study on treatment outcomes and cardiopulmonary function.

Key Points

• This research aims to evaluate treatment outcomes and cardiopulmonary function in beta thalassemia patients with pulmonary hypertension (PH).
• Conducted a prospective cohort study focusing on beta thalassemia patients with PH.
• Assessed the impact of vasodilatory treatment on cardiopulmonary metrics.
• Measured outcomes such as 6-minute walk test (6MWT), proBNP levels, and E/e' ratio.
• Vasodilatory treatment led to significant improvements in 6MWT performance.
• ProBNP levels decreased, indicating better heart function.
• E/e' ratio improved, suggesting enhanced right ventricular function.